protein

Recombinant Human Bone Morphogenetic protein-4

MBS142238

0.002 mg

140 USD

Recombinant Protein

Recombinant Human Bone Morphogenetic protein-4

Morphogenetic protein-4

BMP 4 Human; Bone Morphogenetic Protein-4 Human Recombinant; BMP4; ZYME; BMP2B; BMP2B1

bone morphogenetic protein 4 preproprotein; Bone morphogenetic protein 4; bone morphogenetic protein 4; BMP-2B; BMP-4; bone morphogenetic protein 2B; bone morphogenetic protein 4; Bone morphogenetic protein 2B; BMP-2B

BMP 4

BMP4; BMP4; ZYME; BMP2B; OFC11; BMP2B1; MCOPS6; BMP2B; DVR4; BMP-4; BMP-2B

BMP4_HUMAN

E Coli

408

SPKHHSQRAR KKNKNCRRHS LYVDFSDVGW NDWIVAPPGY QAFYCHGDCP FPLADHLNST NHAIVQTLVN SVNSSIPKAC CVPTELSAIS MLYLDEYDKV VLKNYQEMVV EGCGCR.

Greater than 95.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.

BMP-4 was lyophilized from a 0.2?m filtered concentrated (1mg/ml) solution in 20mM Na2CO3 buffer, pH 9.0. Sterile Filtered White lyophilized (freeze-dried) powder.

Lyophilized Bone Morphogenetic Protein-4 although stable at room temperature for 3 weeks, should be stored desiccated below -18 degree C. Upon reconstitution BMP4 should be stored at 4 degree C between 2-7 days and for future use below -18 degree C.For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please prevent freeze-thaw cycles.

Solubility: It is recommended to reconstitute the lyophilized Bone Morphogenetic Protein-4 in sterile 18M-cm H2O not less than 100 ug/ml, which can then be further diluted to other aqueous solutions.

CYTOKINES AND GROWTH FACTORS; Cytokines; Bone Morphogenetic Protein

Description: Bone Morphogenetic Protein-4 Human Recombinant produced in E Coli is a monomeric, non-glycosylated, Polypeptide chain containing 116 amino acids and having a molecular mass of 13kDa. The BMP-4 is purified by proprietary chromatographic techniques. Introduction: The protein encoded by this gene is a member of the bone morphogenetic protein family which is part of the transforming growth factor-beta superfamily. The superfamily includes large families of growth and differentiation factors. Bone morphogenetic proteins were originally identified by an ability of demineralized bone extract to induce endochondral osteogenesis in vivo in an extraskeletal site. This particular family member plays an important role in the onset of endochondral bone formation in humans, and a reduction in expression has been associated with a variety of bone diseases, including the heritable disorder Fibrodysplasia Ossificans Progressiva. Alternative splicing in the 5' untranslated region of this gene has been described and three variants are described, all encoding an identical protein.

157276593

NP_001193.2

NM_001202.3

P12644

46,555 Da

Adipogenesis Pathway (198832); BMP Signaling Pathway (1084755); BMP Signaling Pathway (1108218); Basal Cell Carcinoma Pathway (83113); Basal Cell Carcinoma Pathway (525); Cardiac Progenitor Differentiation Pathway (712094); Elastic Fibre Formation Pathway (730310); Extracellular Matrix Organization Pathway (576262); Glypican 3 Network Pathway (138084); Heart Development Pathway (198802)

The protein encoded by this gene is a member of the bone morphogenetic protein family which is part of the transforming growth factor-beta superfamily. The superfamily includes large families of growth and differentiation factors. Bone morphogenetic proteins were originally identified by an ability of demineralized bone extract to induce endochondral osteogenesis in vivo in an extraskeletal site. This particular family member plays an important role in the onset of endochondral bone formation in humans, and a reduction in expression has been associated with a variety of bone diseases, including the heritable disorder Fibrodysplasia Ossificans Progressiva. Alternative splicing in the 5' untranslated region of this gene has been described and three variants are described, all encoding an identical protein. [provided by RefSeq, Jul 2008]

BMP4: Induces cartilage and bone formation. Also act in mesoderm induction, tooth development, limb formation and fracture repair. Acts in concert with PTHLH/PTHRP to stimulate ductal outgrowth during embryonic mammary development and to inhibit hair follicle induction. Homodimer; disulfide-linked. Interacts with GREM2. Part of a complex consisting of TWSG1 and CHRD. Interacts with the serine proteases, HTRA1 and HTRA3; the interaction with either inhibits BMP4-mediated signaling. The HTRA protease activity is required for this inhibition. Interacts with SOSTDC1. Expressed in the lung and lower levels seen in the kidney. Present also in normal and neoplastic prostate tissues, and prostate cancer cell lines. Belongs to the TGF-beta family. Protein type: Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 14q22-q23. Cellular Component: proteinaceous extracellular matrix; extracellular space; extracellular region. Molecular Function: heparin binding; protein binding; growth factor activity; cytokine activity; transforming growth factor beta receptor binding; chemoattractant activity. Biological Process: negative regulation of MAP kinase activity; extracellular matrix organization and biogenesis; renal system process; macrophage differentiation; activation of MAPKK activity; positive regulation of apoptosis; positive regulation of transcription, DNA-dependent; negative regulation of chondrocyte differentiation; lymphoid progenitor cell differentiation; telencephalon regionalization; germ cell development; post-embryonic development; BMP signaling pathway; regulation of protein import into nucleus; positive regulation of endothelial cell differentiation; positive chemotaxis; chondrocyte differentiation; erythrocyte differentiation; mesonephros development; kidney development; endochondral ossification; regulation of odontogenesis of dentine-containing teeth; negative regulation of immature T cell proliferation in the thymus; positive regulation of cardiac muscle fiber development; specification of organ position; monocyte differentiation; neuron fate commitment; embryonic cranial skeleton morphogenesis; negative regulation of striated muscle development; branching morphogenesis of a tube; negative regulation of mitosis; positive regulation of epidermal cell differentiation; negative regulation of phosphorylation; steroid hormone mediated signaling; positive regulation of transcription from RNA polymerase II promoter; hemopoietic progenitor cell differentiation; positive regulation of endothelial cell proliferation; embryonic digit morphogenesis; negative regulation of transcription, DNA-dependent; alveolus development; positive regulation of epithelial cell proliferation; negative regulation of apoptosis; positive regulation of protein binding; positive regulation of smooth muscle cell proliferation; positive regulation of collagen biosynthetic process; cloacal septation; negative regulation of transcription from RNA polymerase II promoter; embryonic hindlimb morphogenesis; negative regulation of cell cycle; odontogenesis; smooth muscle development; negative regulation of cell proliferation; inner ear receptor cell differentiation; ureteric bud development; intermediate mesodermal cell differentiation; regulation of smooth muscle cell differentiation; dorsoventral neural tube patterning; positive regulation of BMP signaling pathway; negative regulation of epithelial cell proliferation; smoothened signaling pathway; common-partner SMAD protein phosphorylation; negative regulation of T cell differentiation in the thymus; positive regulation of bone mineralization; positive regulation of ossification; odontogenesis of dentine-containing teeth; osteoblast differentiation; positive regulation of osteoblast differentiation; blood vessel endothelial cell proliferation during sprouting angiogenesis; telencephalon development; ureteric bud branching; pituitary gland development; regulation of cell fate commitment; neural tube closure; positive regulation of protein amino acid phosphorylation; negative regulation of myoblast differentiation; positive regulation of neuron differentiation; mesodermal cell fate determination; anterior/posterior axis specification. Disease: Orofacial Cleft 11; Microphthalmia, Syndromic 6

0.002 mg

140 USD

0.01 mg

205

1 mg

2780